dexamethasone,nirogacestat,lenalidomide,teclistamab,daratumumab,pomalidomide,bortezomib
takeda,springworks therapeutics,janssen,genmab,bms
['majestec-2', 'mmsm', 'lenalidomide', 'daratumumab', ' lena', 'dexamethasone', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'effector ']
#ash22 #mmsm majestec-2, a phase1b 32 pts, orr 94% 2 fatal aes (infections): 6%. g3/4 pneumonia infections in 5 pts (16%) g3/4 infections in more than 1/3 of patients. this is extremely concerning. look at table with infections 
Assistant professor @UAMSMyeloma. Alumni heme/onc @bcmhouston, clinical research/biostat @UMich.Focus on plasma cell disorders & health disparities